|
Pre-Eclampsia
|
0.600 |
Biomarker
|
phenotype |
CTD_human |
This locus is near the FLT1 gene encoding Fms-like tyrosine kinase 1, providing biological support, as a placental isoform of this protein (sFlt-1) is implicated in the pathology of preeclampsia.
|
28628106 |
2017 |
|
Pre-Eclampsia
|
0.600 |
SusceptibilityMutation
|
phenotype |
ORPHANET |
This locus is near the FLT1 gene encoding Fms-like tyrosine kinase 1, providing biological support, as a placental isoform of this protein (sFlt-1) is implicated in the pathology of preeclampsia.
|
28628106 |
2017 |
|
Pre-Eclampsia
|
0.600 |
Biomarker
|
phenotype |
LHGDN |
Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study.
|
19064815 |
2009 |
|
Pre-Eclampsia
|
0.600 |
Biomarker
|
phenotype |
LHGDN |
First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia.
|
18771978 |
2008 |
|
Pre-Eclampsia
|
0.600 |
AlteredExpression
|
phenotype |
LHGDN |
Apoptotic levels do not correlate with Flt1 in preeclampsia placentae and are not regulated by in vivo exposure to the antihypertensives clonidine and hydralazine.
|
19003637 |
2008 |
|
Pre-Eclampsia
|
0.600 |
AlteredExpression
|
phenotype |
LHGDN |
However, an increased expression of ENG and FLT1 was detected by qRT-PCR in the PE + SGA group.
|
18330824 |
2008 |
|
Pre-Eclampsia
|
0.600 |
Biomarker
|
phenotype |
LHGDN |
Cigarette smoke exposure and angiogenic factors in pregnancy and preeclampsia.
|
18566591 |
2008 |
|
Pre-Eclampsia
|
0.600 |
Biomarker
|
phenotype |
LHGDN |
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.
|
18175241 |
2008 |
|
Pre-Eclampsia
|
0.600 |
Biomarker
|
phenotype |
CTD_human |
Placental expression of ceruloplasmin in pregnancies complicated by severe preeclampsia.
|
18679377 |
2008 |
|
Pre-Eclampsia
|
0.600 |
Biomarker
|
phenotype |
LHGDN |
A cross-sectional study was conducted to determine the concentrations of the soluble form of VEGFR-1 in plasma obtained from normal pregnant women (n = 135), women with SGA fetuses (n = 53), and patients with preeclampsia (n = 112).
|
18175242 |
2008 |
|
Pre-Eclampsia
|
0.600 |
Biomarker
|
phenotype |
LHGDN |
Elevated sVEGFR-1 serum levels and up-regulated membranous VEGFR-1 expression in placenta denote abnormality in VEGF-mediated function in all placental cells, and thus may contribute to etiopathogenesis of pre-eclampsia.
|
18992679 |
2008 |
|
Pre-Eclampsia
|
0.600 |
GeneticVariation
|
phenotype |
LHGDN |
A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia.
|
18515749 |
2008 |
|
Pre-Eclampsia
|
0.600 |
AlteredExpression
|
phenotype |
LHGDN |
Circulating levels of the antiangiogenic marker soluble FMS-like tyrosine kinase 1 are elevated in women with pregestational diabetes and preeclampsia: angiogenic markers in preeclampsia and preexisting diabetes.
|
17259514 |
2007 |
|
Pre-Eclampsia
|
0.600 |
AlteredExpression
|
phenotype |
LHGDN |
Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review.
|
17197602 |
2007 |
|
Pre-Eclampsia
|
0.600 |
Biomarker
|
phenotype |
LHGDN |
Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia.
|
17982238 |
2007 |
|
Pre-Eclampsia
|
0.600 |
Biomarker
|
phenotype |
LHGDN |
We describe recent evidence that supports a novel mechanism in which a maladaptive shift in placental production of angiogenic factors such as soluble fms-like tyrosine kinase 1 (a circulating antiangiogenic protein) may play an important role in the pathogenesis of preeclampsia.
|
15817508 |
2005 |
|
Pre-Eclampsia
|
0.600 |
Biomarker
|
phenotype |
LHGDN |
Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies.
|
16021053 |
2005 |
|
Pre-Eclampsia
|
0.600 |
Biomarker
|
phenotype |
LHGDN |
We asked whether, as with preeclampsia, sFlt-1 is increased and free PlGF is decreased in villous placenta and maternal serum of normotensive women with small-for-gestational-age (SGA) neonates.
|
15886253 |
2005 |
|
Pre-Eclampsia
|
0.600 |
AlteredExpression
|
phenotype |
LHGDN |
Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia.
|
15472115 |
2004 |